Watson reportedly aims for Actavis buyout agreement this month

04/12/2012 | Reuters

Watson Pharmaceuticals is on track to seal a deal this month to acquire Actavis for about $6 billion, sources said. Investors think such an acquisition would enable Watson to compete effectively with larger companies such as Teva Pharmaceutical Industries and Novartis division Sandoz.

View Full Article in: